title: Influence of ACTH on the effects of imipramine, desipramine and lithium on duration of immobility of rats in the forced swim test.
abstract: We examined the effects of adrenocorticotropic hormone (ACTH) on the immobilization of rats in the forced swim test with the administration of imipramine, desipramine, or lithium. A single administration of either imipramine (10-30 mg/kg, i.p.) or desipramine (30 mg/kg, i.p.) significantly decreased the duration of immobility in normal rats in a dose-dependent manner. Lithium (10-100 mg/kg, p.o.), however, had no affect on the performance of rats in the forced swim test. ACTH (100 microg/day), administered subcutaneously to rats for 1, 3, 7, and 14 days, had no apparent effect on the duration of immobility in this test. The immobility-decreasing effect induced by a single administration of either imipramine (10-30 mg/kg, i.p.) or desipramine (30 mg/kg, i.p.) was blocked by chronic administration of ACTH for 3-14 days. The reduction of immobility, induced by chronic administration of imipramine (10 mg/kg, i.p.) for 15 days, was blocked by treatment with ACTH for 14 days. When lithium (100 mg/kg, p.o.) was administered for 15 days concurrently with imipramine (10 mg/kg, i.p.), we observed a significant decrease in immobility in rats treated with ACTH for 14 days. We suggest that chronic treatment of rats with ACTH may prove to be an effective model of tricyclic antidepressants-treatment-resistant depression.
authors.affiliation: Department of Hospital Pharmacy, Okayama University Medical School, 2-5-1, Shikata-cho, Okayama 700-8558, Japan.
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Kitamura
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Araki
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Gomita
mesh_terms: D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D018692:Antimanic Agents / Q000494:pharmacology / Q000627:therapeutic use; D003366:Cosyntropin / Q000494:pharmacology / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy / Q000503:physiopathology; D003891:Desipramine / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects / Q000502:physiology; D007099:Imipramine / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D007103:Immobilization / Q000502:physiology; D018021:Lithium Chloride / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D010913:Pituitary-Adrenal System / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D013550:Swimming / Q000502:physiology* / Q000523:psychology
chemical_list: D000929:Antidepressive Agents, Tricyclic; D018692:Antimanic Agents; D003366:Cosyntropin; D018021:Lithium Chloride; D007099:Imipramine; D003891:Desipramine